Flow and volume responses after routine salbutamol reversibility testing in mild to very severe COPD

Respiratory Medicine

Volumn 101, Issue 6, 2007, Pages 1355-1362

  Schermer, Tjard ^a   Heijdra, Yvonne ^a   Zadel, Sabina ^a   van den Bemt, Lisette ^a,b   Boonman de Winter, Leandra ^b   Dekhuijzen, Richard ^a   Smeele, Ivo ^b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Stichting Huisartsen Laboratorium   (Netherlands)

Author keywords

Bronchodilator; COPD; General practice; Reversibility testing; Spirometry

Indexed keywords

BRONCHODILATING AGENT; LONG ACTING DRUG; SALBUTAMOL; SHORT ACTING DRUG;

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; CORRELATION FUNCTION; DISEASE COURSE; DISEASE SEVERITY; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; HYPOTHESIS; LINEAR REGRESSION ANALYSIS; LUNG COMPLIANCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RESPIRATORY AIRFLOW; SMOKING; SPIROMETRY; STATISTICAL SIGNIFICANCE;

ADULT; AGED; AGED, 80 AND OVER; ALBUTEROL; BRONCHODILATOR AGENTS; CROSS-SECTIONAL STUDIES; FAMILY PRACTICE; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SEVERITY OF ILLNESS INDEX; SMOKING; SPIROMETRY; VITAL CAPACITY;

EID: 34247616048     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2006.09.024     Document Type: Article

References (24)

1. Global Initiative for Chronic Obstructive Lung Disease; 〈www.goldcopd.com〉. (accessed: 30.1.06).
2. Hay J.G., Stone P., Carter J., Church S., Eyre-Brook A., Pearson M.G., et al. Bronchodilator reversibility, exercise performance and breathlessness in stable chronic obstructive pulmonary disease. Eur Respir J 5 (1992) 659-664
3. Anthonisen N.R., and Wright E.C. Bronchodilator response in chronic obstructive pulmonary disease. Am Rev Respir Dis 133 (1986) 814-819
4. Pellegrino R., and Brusasco V. Lung hyperinflation and flow limitation in chronic airway obstruction. Eur Respir J 10 3 (1997) 543-549
5. Ayres S.M., Griesbach S.J., Reimold F., and Evans R.G. Bronchial component in chronic obstructive lung disease. Am J Med 57 2 (1974) 183-191
6. Girard W.M., and Light R.W. Should the FVC be considered in evaluating response to bronchodilator?. Chest 84 1 (1983) 87-89
7. Tantucci C., Duguet A., Similowski T., Zelter M., Derenne J.P., and Milic-Emili J. Effect of salbutamol on dynamic hyperinflation in chronic obstructive pulmonary disease patients. Eur Respir J 12 4 (1998) 799-804
8. Calverley P.M., and Koulouris N.G. Flow limitation and dynamic hyperinflation: key concepts in modern respiratory physiology. Eur Respir J 25 1 (2005) 186-199
9. O'Donnell D.E., Voduc N., Fitzpatrick M., and Webb K.A. Effect of salmeterol on the ventilatory response to exercise in chronic obstructive pulmonary disease. Eur Respir J 24 1 (2004) 86-94
10. Man W.D., Mustfa N., Nikoletou D., Kaul S., Hart N., Rafferty G.F., et al. Effect of salmeterol on respiratory muscle activity during exercise in poorly reversible COPD. Thorax 59 6 (2004) 471-476
11. O'Donnell D.E., Forkert L., and Webb K.A. Evaluation of bronchodilator responses in patients with "irreversible" emphysema. Eur Respir J 18 6 (2001) 914-920
12. Puente-Maestu L., Garcia de P.J., Martinez-Abad Y., Ruiz de Ona J.M., Llorente D., and Cubillo J.M. Dyspnea, ventilatory pattern, and changes in dynamic hyperinflation related to the intensity of constant work rate exercise in COPD. Chest 128 2 (2005) 651-656
13. Cerveri I., Pellegrino R., Dore R., Corsico A., Fulgoni P., van de Woestijne K.P., et al. Mechanisms for isolated volume response to a bronchodilator in patients with COPD. J Appl Physiol 88 6 (2000) 1989-1995
14. O'Brien C., Guest P.J., Hill S.L., and Stockley R.A. Physiological and radiological characterisation of patients diagnosed with chronic obstructive pulmonary disease in primary care. Thorax 55 8 (2000) 635-642
15. Chang J.T., Moran M.B., Cugell D.W., and Webster Jr. J.R. COPD in the elderly. A reversible cause of functional impairment. Chest 108 3 (1995) 736-740
16. Quanjer P.H., Tammeling G.J., Cotes J.E., Pedersen O.F., Peslin R., and Yernault J.C. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl 16 (1993) 5-40
17. American Thoracic Society. Standardization of spirometry: 1994 update. Am J Respir Crit Care Med 152 (1995) 1107-1136
18. Chanez P., Vignola A.M., Shaugnessy T., Enander I., Li D., Jeffery P.K., et al. Corticosteroid reversibility in COPD is related to features of asthma. Am J Respir Crit Care Med 155 (1997) 1529-1534
19. Grootendorst D.C., and Rabe K.F. Mechanisms of bronchial hyperreactivity in asthma and chronic obstructive pulmonary disease. Proc Am Thorac Soc 1 (2004) 77-87
20. Calverley P.M., Burge P.S., Spencer S., Anderson J.A., and Jones P.W. Bronchodilator reversibility testing in chronic obstructive pulmonary disease. Thorax 58 8 (2003) 659-664
21. Hoogendoorn M., Feenstra T.L., Schermer T.R., Hesselink A.E., and Rutten-van Molken M.P. Severity distribution of chronic obstructive pulmonary disease (COPD) in Dutch general practice. Respir Med 100 (2006) 83-86
22. Dorinsky P.M., Reisner C., Ferguson G.T., Menjoge S.S., Serby C.W., and Witek Jr. T.J. The combination of ipratropium albuterol optimizes pulmonary function reversibility testing in patients with COPD. Chest 115 4 (1999) 966-971
23. Levin D.C., Little K.S., Laughlin K.R., Galbraith J.M., Gustman P.M., Murphy D., et al. Addition of anticholinergic solution prolongs bronchodilator effect of beta 2 agonists in patients with chronic obstructive pulmonary disease. Am J Med 100 1A (1996) 40S-48S
24. Cerveri I., Dore R., Corsico A., Zoia M.C., Pellegrino R., Brusasco V., et al. Assessment of emphysema in COPD: a functional and radiologic study. Chest 125 5 (2004) 1714-1718